Share This Page
HALFLYTELY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Halflytely, and what generic alternatives are available?
Halflytely is a drug marketed by Braintree and is included in one NDA.
The generic ingredient in HALFLYTELY is bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride profile page.
US Patents and Regulatory Information for HALFLYTELY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braintree | HALFLYTELY | bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride | FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL | 021551-003 | Jul 16, 2010 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
HALFLYTELY (LAXATIVE) Investment Scenario and Fundamentals: Patent, Exclusivity, FDA, and Generic Entry Risk
HALFLYTELY is a prescription-strength bowel-cleansing product with limited patent-driven upside in the near term relative to branded prescription small-molecule launches because the asset class typically faces fast generic substitution once core IP and regulatory exclusivities expire. The investment case is therefore driven by (1) how long HALFLYTELY’s Orange Book-listed exclusivities and patents block “AB-rated” ANDAs, (2) whether meaningful formulation or process patents survive beyond the base expiration, and (3) the extent of settlement-based brand protection (typically 180-day exclusivity and/or agreed launch timing) if Paragraph IV challenges are filed. On fundamentals, the product’s demand profile is tied to colonoscopy volumes, payer coverage, and manufacturing continuity; price elasticity is high once generics enter.
Actionable bottom line: treat HALFLYTELY as a revenue-lite, lifecycle-exposed specialty consumable where the primary investment “alpha” comes from patent cliff timing, Paragraph IV landscape, and settlement/entry sequencing rather than from molecule re-rating.
What is HALFLYTELY and how does it make money commercially?
HALFLYTELY is a bowel-cleansing laxative used to prepare the colon for endoscopic procedures such as colonoscopy. The commercial model for bowel preps is characterized by:
- Procedure-driven demand: prescriptions scale with endoscopy capacity and screening program uptake.
- Payer pressure: formularies shift quickly toward the lowest net cost product.
- Switching behavior: clinicians commonly switch within the same therapeutic class once an AB-rated generic is available.
- Procurement bundling: health systems often consolidate suppliers through purchasing contracts after generic entry.
Investment implications
- Revenue durability depends on how long brand exclusivity delays generic substitution and on whether fewer competitors remain on the market during manufacturing outages.
- Margin trajectories usually compress after generic launches as WAC-to-net spreads narrow.
What is the FDA regulatory status of HALFLYTELY (Orange Book, RLD, and approval pathway)?
HALFLYTELY’s ability to sustain pricing rests on FDA-listed patent and exclusivity coverage in the Orange Book for the approved dosage forms.
What to check in the Orange Book for HALFLYTELY
- Listed active ingredients and dosage forms (solution powder/sachet configuration vs alternative presentations).
- Listed drug product patents and method-of-use patents.
- Exclusivity markers (for example, 5-year new chemical entity exclusivity, 3-year new clinical investigation exclusivity, or composition/exclusivity tied to supplements).
- Any pediatric exclusivity attachment.
Investment implications
- If HALFLYTELY’s Orange Book coverage is dominated by older patents with imminent expiration, the market typically prices the asset as a “generic clock” rather than as a durable brand.
Which patents protect HALFLYTELY and what parts of the value chain do they cover?
For bowel-cleansing products, patent portfolios typically fall into three buckets:
- Composition and formulation patents (e.g., specific ingredient ratios, electrolytes, flavoring or taste-masking).
- Method-of-use patents (instructional regimens and specific dosing timing).
- Manufacturing and process patents (granulation, mixing, drying, packaging formats, stability).
How this matters for generic entry
- ANDA “sameness” is evaluated at the level of active ingredient identity, route, dosage form, strength, and labeling equivalence.
- Generic sponsors can often design around formulation patents if the brand coverage is narrow or if method-of-use claims do not control dosing instructions they must include.
- If the brand has multiple overlapping drug product patents, generic entry can be delayed through litigation and settlement timing.
How many years of exclusivity does HALFLYTELY have, and when does it lose exclusivity?
HALFLYTELY’s exclusivity profile is determined by Orange Book exclusivity entries and the expiration dates of the most restrictive listed patents. The practical exclusivity clock for investors is:
- Regulatory exclusivity: stops ANDA approval for a period unless an exception applies.
- Patent exclusivity: stops approval or blocks commercial marketing until patents expire or are carved out by litigation outcomes.
- 180-day exclusivity: can delay competitor entry after a successful Paragraph IV challenge, depending on first-filer status and forfeiture conditions.
Investment implications
- If HALFLYTELY has no long tail of exclusivity beyond already-expired product patents, the competitive horizon is governed by patent litigation outcomes and generic launch readiness.
- If settlement agreements exist, the effective exclusivity can extend beyond the “paper” expiration.
What are the HALFLYTELY patent expiration dates (drug product and method patents)?
A high-integrity expiration schedule requires the Orange Book patent list for HALFLYTELY and their individual expiration dates. That schedule is the core input for valuation modeling, including:
- Earliest blocking patent expiry
- Last blocking patent expiry
- Any pediatric exclusivity extensions
- Any terminal disclaimers affecting enforceability
Investment implications
- Investors should value HALFLYTELY primarily off the last enforceable blocking date, not the earliest patent date.
What generic entry risks exist for HALFLYTELY, including Paragraph IV challenges?
Generic entry risk is driven by:
- Whether any ANDA applicants have filed Paragraph IV certifications stating non-infringement or invalidity.
- Whether those challenges are the first-filer (triggering 180-day exclusivity).
- Whether the brand files for and wins a preliminary injunction or reaches a settlement that sets launch timing.
Risk map investors typically model
- Stage 1: Orange Book patent list identifies the blocking claims.
- Stage 2: Paragraph IV filing by generic (or multiple applicants).
- Stage 3: District court litigation timeline and outcomes (dismissal, summary judgment, settlement, infringement finding).
- Stage 4: Settlement that fixes launch date or triggers delayed entry.
- Stage 5: At-launch number of products and pricing behavior.
Investment implications
- If multiple Paragraph IV filings cluster around the same expiration window, market entry can be rapid and pricing can collapse faster than historical single-launch patterns.
- If litigation is resolved via settlement with a fixed deferred launch, revenue can be protected through the settlement date even after earlier patent expiry.
How strong is the patent estate for HALFLYTELY (scope, enforceability, and design-around risk)?
Patent strength in this class is usually assessed on:
- Claim scope: narrow claims are easier for generics to design around.
- Claim type: method-of-use and formulation patents have different “label control” dynamics.
- Validity posture: if the portfolio has heavy overlap with prior art, generic invalidity arguments tend to be credible.
- Litigation history: repeated losses or settlements can signal enforceability constraints.
Investment implications
- If claims are narrow and design-around is straightforward, investors should treat the portfolio as blocking only until the earliest expiry or settlement-limited period.
- If the portfolio includes multiple layered patents that generics cannot bypass without risking infringement, the asset has better odds of delayed multi-generic competition.
What patent litigation affects HALFLYTELY, and what settlement agreements are in play?
Litigation affects not just timelines but also who launches:
- Settlements commonly include agreed dates, stipulated facts, or non-infringement/non-interference clauses.
- 180-day exclusivity can change the economics by enabling one generic to price closer to brand for a short period.
Investment implications
- The market reacts to settlement announcements because they fix launch calendars and shape expected number of entrants.
- In bowel prep categories, rapid substitution after first entry can compress profits even if only one generic launches initially.
How does HALFLYTELY compare with other colon cleansing products on market competitiveness?
Bowel prep competition includes oral electrolyte solutions and alternative regimens. Key comparability variables:
- Dosing regimen complexity (split dosing vs single dosing)
- Volume burden (patient tolerability affects adherence)
- Taste and adherence (formulation and flavor)
- Coverage and net price (payer formulary inclusion)
- Manufacturing continuity (stockouts can shift prescriptions)
Investment implications
- If HALFLYTELY’s competitive position is weakened by formularies favoring alternate products, even before generic entry, the revenue baseline can erode.
- If the product has strong formulary share and clinicians prefer its tolerability, generic entry can still cause margin compression but may not eliminate demand.
What formulations are protected by HALFLYTELY (and what’s the design-around path for ANDAs)?
For an ANDA, design-around is constrained by FDA requirements:
- Generic must be bioequivalent in relevant measures where applicable and meet labeling equivalence requirements.
- If formulation patents cover specific ingredient ratios or stabilizing agents, generics may alter composition within acceptable equivalence boundaries.
- Taste-masking and excipient-related patents often face more “design-around” flexibility depending on claim scope.
Investment implications
- Narrow formulation patents reduce blocking power, increasing the likelihood of faster ANDA approval and launch.
- Broader formulation patents can delay entry if the generic must change beyond acceptable equivalence.
What manufacturing/IP barriers exist for HALFLYTELY (scale, stability, packaging, and shelf life)?
Even with regulatory approval, launch depends on:
- Ability to manufacture at commercial scale with stable quality.
- Stability and packaging integrity (shelf life and container-closure systems).
- Compliance history and inspection outcomes.
Investment implications
- If the brand retains proprietary manufacturing processes or stability claims, generics may face operational delays.
- Manufacturing interruptions can create interim supply scarcity where the brand retains some pricing power.
What is the competitive landscape for HALFLYTELY after generic entry (pricing and share outcomes)?
Bowel prep categories often behave like this:
- First generic entry triggers substantial brand share loss.
- Subsequent entrants increase discounting and net-price erosion.
- Payer contracts migrate toward the lowest net-cost product with acceptable patient outcomes.
Investment implications
- Model a steep margin curve in the first 6 to 18 months post-entry.
- Estimate “survivor” scenarios where some regional or health-system formularies keep an older product for contractual reasons, but the ceiling on brand price usually falls sharply.
Which companies are likely challengers or next entrants for HALFLYTELY?
Generic challengers tend to be experienced ANDA filers that maintain portfolios in GI and electrolytes. The identity of likely entrants depends on:
- Number of Paragraph IV filings.
- ANDA applicants appearing in Orange Book dispute entries.
- Manufacturing footprint and capability for this specific product format.
Investment implications
- Concentration of filings among a few large generic firms can stabilize post-launch competition if one launches later or faces manufacturing delays.
- Broad clustering among multiple filers typically accelerates price convergence.
Key investment scenario: base case, downside case, and upside case for HALFLYTELY
Because HALFLYTELY’s value driver is exclusivity and generic blocking dates, scenario modeling should anchor on:
- Last blocking patent expiration date
- Probability of Paragraph IV challenges and injunction/settlement outcomes
- Number and timing of generic launches
- Net price compression curve
Base case
- Generic entry occurs soon after last blocking date.
- One or two entrants launch initially; pricing drops but does not collapse immediately due to contract inertia.
Downside case
- Multiple ANDA launches align with the same window.
- Accelerated substitution plus aggressive pricing leads to rapid margin compression and revenue decline.
Upside case
- Settlement defers launch beyond the last blocking date or manufacturing delays slow entry.
- Brand maintains higher net pricing for longer via contract renewals and supply availability.
Key Takeaways
- HALFLYTELY’s investment profile is dominated by patent and exclusivity timing plus Paragraph IV and settlement dynamics, not molecule differentiation.
- Core underwriting inputs are the Orange Book patent list, the last enforceable blocking date, and the litigation/settlement calendar.
- Post-generic economics are typically characterized by steep net-price erosion and rapid formulary migration within GI bowel prep classes.
- Upside is most likely tied to delayed generic entry (settlement or manufacturing constraints). Downside is rapid multi-entrant launch leading to faster share and margin loss.
FAQs
- How do Paragraph IV challenges for HALFLYTELY affect the timing of generic approval and launch?
- What Orange Book exclusivities matter most for bowel cleansing products like HALFLYTELY?
- Can formulation patents for HALFLYTELY be designed around without changing labeling?
- How does first-filer 180-day exclusivity impact pricing for HALFLYTELY after generic entry?
- What manufacturing constraints typically delay or accelerate launches of bowel prep ANDAs?
References
No sources were provided in the prompt, and no Orange Book, FDA approval, or patent-literal citations were included; therefore, no references can be listed.
More… ↓
